Dual IFN-γ/hypoxia priming enhances immunosuppression of mesenchymal stromal cells through regulatory proteins and metabolic mechanisms
Journal of Immunology and Regenerative Medicine · 2018
DOI: 10.1016/j.regen.2018.01.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Immunology and Regenerative Medicine, 2018. Verfasst von Holly M Wobma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Columbia University, New York, NY, USA. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, NIH.
Abstract (Originalsprache)
The immunosuppressive capacity of human mesenchymal stromal cells (MSCs) renders them promising candidates for treating diverse immune disorders. However, after hundreds of clinical trials, there are still no MSC therapies approved in the United States. MSCs require specific cues to adopt their immunosuppressive phenotype, and yet most clinical trials use cells expanded in basic culture medium and growth conditions. We propose that priming MSCs prior to administration will improve their therapeutic efficacy. Interferon-gamma (IFN-γ) priming are cues common to situations of immune escape that have individually shown promise as MSC priming cues but have not been systematically compared. Using mixed lymphocyte reactions, we show that priming MSCs with either cue alone improves T-cell inhibition. However, combining the two cues results in additive effects and markedly enhances the immunosuppressive phenotype of MSCs. We demonstrate that IFN-γ induces expression of numerous immunosuppressive proteins (IDO, PD-L1, HLA-E, HLA-G), whereas hypoxia switches MSCs to glycolysis, causing rapid glucose consumption and production of T-cell inhibitory lactate levels. Dual IFN-γ/hypoxia primed MSCs display both attributes and have even higher induction of immunosuppressive proteins over IFN-γ priming alone (IDO and HLA-G), which may reflect another benefit of metabolic reconfiguration.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Columbia University, New York, NY, USA.
- Columbia Center for Translational Immunology, Columbia University, New York, NY, USA.
- Department of Pathobiology, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Pathology, Columbia University, New York, NY, USA.
- Department of Medicine, Columbia University, New York, NY, USA.
- Quantitative Proteomics and Metabolomics Center, Columbia University, New York, NY, USA.
Förderung
- NIBIB NIH HHS
- NIH
Zitieren
APA
Wobma, H. M., Kanai, M., Ma, S. P., Shih, Y., Li, H. W., Duran-Struuck, R., Winchester, R., Goeta, S., Brown, L. M., & Vunjak-Novakovic, G. (2018). Dual IFN-γ/hypoxia priming enhances immunosuppression of mesenchymal stromal cells through regulatory proteins and metabolic mechanisms. Journal of Immunology and Regenerative Medicine. https://doi.org/10.1016/j.regen.2018.01.001
Vancouver
Wobma HM, Kanai M, Ma SP, Shih Y, Li HW, Duran-Struuck R, et al. Dual IFN-γ/hypoxia priming enhances immunosuppression of mesenchymal stromal cells through regulatory proteins and metabolic mechanisms. Journal of Immunology and Regenerative Medicine. 2018. doi:10.1016/j.regen.2018.01.001
BibTeX
@article{Wobma2018,
author = {Wobma, Holly M and Kanai, Mariko and Ma, Stephen P and Shih, Ying and Li, Hao Wei and Duran-Struuck, Raimon and Winchester, Robert and Goeta, Shahar and Brown, Lewis M and Vunjak-Novakovic, Gordana},
title = {Dual IFN-γ/hypoxia priming enhances immunosuppression of mesenchymal stromal cells through regulatory proteins and metabolic mechanisms},
journal = {Journal of Immunology and Regenerative Medicine},
year = {2018},
doi = {10.1016/j.regen.2018.01.001}
}
EUVIMED